enGene Holdings Inc. (NASDAQ:ENGN) Short Interest Down 31.5% in February

enGene Holdings Inc. (NASDAQ:ENGN) was the recipient of a large decline in short interest during the month of February. As of February 13th, there was short interest totaling 1,501,696 shares, a decline of 31.5% from the January 29th total of 2,192,033 shares. Based on an average daily volume of 327,514 shares, the days-to-cover ratio is currently 4.6 days. Approximately 2.5% of the shares of the company are sold short. Approximately 2.5% of the shares of the company are sold short. Based on an average daily volume of 327,514 shares, the days-to-cover ratio is currently 4.6 days.

enGene Trading Up 0.8%

enGene stock opened at $10.11 on Friday. The business has a 50 day moving average price of $9.57 and a two-hundred day moving average price of $7.84. The company has a quick ratio of 6.30, a current ratio of 6.30 and a debt-to-equity ratio of 0.09. enGene has a 12 month low of $2.65 and a 12 month high of $12.25. The stock has a market cap of $677.27 million, a price-to-earnings ratio of -4.41 and a beta of -0.29.

enGene (NASDAQ:ENGN) last released its quarterly earnings data on Monday, December 22nd. The company reported ($0.73) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.18). As a group, equities analysts forecast that enGene will post -1.56 EPS for the current year.

Hedge Funds Weigh In On enGene

Hedge funds have recently made changes to their positions in the business. Cresset Asset Management LLC acquired a new stake in shares of enGene during the 2nd quarter valued at about $36,000. Affinity Asset Advisors LLC acquired a new stake in enGene during the second quarter valued at approximately $280,000. Paloma Partners Management Co bought a new stake in shares of enGene in the 2nd quarter valued at approximately $38,000. PFS Partners LLC acquired a new position in shares of enGene in the 3rd quarter worth approximately $61,000. Finally, Raymond James Financial Inc. lifted its position in shares of enGene by 383.6% during the 3rd quarter. Raymond James Financial Inc. now owns 10,000 shares of the company’s stock worth $68,000 after buying an additional 7,932 shares during the period. Institutional investors and hedge funds own 64.16% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on ENGN. Citigroup reaffirmed a “market outperform” rating on shares of enGene in a report on Monday, January 5th. Oppenheimer reaffirmed an “outperform” rating and issued a $33.00 price target (up from $30.00) on shares of enGene in a research report on Wednesday, November 12th. HC Wainwright reissued a “buy” rating and set a $25.00 price objective on shares of enGene in a research report on Wednesday, December 3rd. Morgan Stanley lifted their price target on enGene from $18.00 to $19.00 and gave the stock an “overweight” rating in a research report on Wednesday, November 12th. Finally, Jefferies Financial Group assumed coverage on enGene in a research report on Friday, January 30th. They issued a “buy” rating and a $28.00 price objective for the company. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $23.29.

enGene Company Profile

enGene, Inc is a clinical‐stage biopharmaceutical company focused on the development of gene‐based therapeutics for oncology. The company’s core technology is the EnGene Delivery Vehicle (EDV) platform, which employs nonliving, bacterially derived minicells to transport therapeutic payloads directly to tumor cells. By combining targeted delivery with potent payloads, enGene aims to improve the precision and efficacy of cancer treatments while reducing off‐target toxicity.

Through its EDV platform, enGene has advanced multiple therapeutic candidates into preclinical and clinical stages.